drugset / Trial / NCT00079638

Comparative Efficacy Evaluation of Lipids When Treated With Niaspan & Statin or Other Lipid-Modifying Therapies-COMPELL

NCT00079638

Phase 4 Completed 300 enrolled Kos Pharmaceuticals
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the effectiveness of first-line treatment using Niaspan (an extended release version of niacin) and statins versus other drugs that lower lipid levels, in subjects with elevated fat levels in their blood (dyslipidemia). Statins are a class of medication that is often prescribed to patients who need to lower their cholesterol levels.

Timeline

Start
2004-04
Primary completion
Completion
2005-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Atorvastatin Small molecule 40 mg
Subject Ezetimibe Unknown 10 mg
Subject Niacin Small molecule 1000 mg
Subject Niacin Small molecule 2000 mg
Subject Rosuvastatin Small molecule 20 mg
Subject Rosuvastatin Small molecule 40 mg
Subject Simvastatin Small molecule 40 mg